What is Zacks Research’s Estimate for Medifast Q2 Earnings?

Medifast, Inc. (NYSE:MED) – Zacks Research decreased their Q2 2025 earnings estimates for shares of Medifast in a report issued on Monday, May 19th. Zacks Research analyst R. Department now forecasts that the specialty retailer will earn $0.00 per share for the quarter, down from their prior estimate of $0.24. The consensus estimate for Medifast’s current full-year earnings is $0.51 per share. Zacks Research also issued estimates for Medifast’s Q3 2025 earnings at $0.06 EPS, Q4 2025 earnings at $0.10 EPS, FY2025 earnings at $0.06 EPS, Q1 2026 earnings at $0.14 EPS, Q2 2026 earnings at $0.18 EPS, Q3 2026 earnings at $0.22 EPS, Q4 2026 earnings at $0.22 EPS, FY2026 earnings at $0.75 EPS, Q1 2027 earnings at $0.13 EPS and FY2027 earnings at $0.51 EPS.

Other analysts also recently issued research reports about the stock. Wall Street Zen raised shares of Medifast from a “hold” rating to a “buy” rating in a report on Thursday, May 1st. DA Davidson reduced their price objective on shares of Medifast from $17.00 to $16.50 and set a “neutral” rating for the company in a research note on Wednesday, February 19th.

Medifast Stock Up 1.6%

Shares of NYSE:MED opened at $13.45 on Thursday. The company has a market cap of $147.83 million, a price-to-earnings ratio of 74.72 and a beta of 0.96. The firm’s 50-day simple moving average is $13.11 and its 200-day simple moving average is $15.54. Medifast has a fifty-two week low of $11.57 and a fifty-two week high of $26.53.

Medifast (NYSE:MED) last announced its quarterly earnings data on Monday, April 28th. The specialty retailer reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.04). Medifast had a net margin of 0.35% and a return on equity of 10.64%. The firm had revenue of $115.73 million during the quarter, compared to analysts’ expectations of $114.85 million.

Hedge Funds Weigh In On Medifast

A number of institutional investors have recently modified their holdings of the company. Acadian Asset Management LLC grew its holdings in Medifast by 41.5% in the first quarter. Acadian Asset Management LLC now owns 385,723 shares of the specialty retailer’s stock valued at $5,193,000 after purchasing an additional 113,111 shares during the period. AQR Capital Management LLC grew its stake in Medifast by 14.5% during the first quarter. AQR Capital Management LLC now owns 199,750 shares of the specialty retailer’s stock worth $2,693,000 after buying an additional 25,366 shares during the period. Amundi grew its stake in Medifast by 43.5% during the first quarter. Amundi now owns 30,439 shares of the specialty retailer’s stock worth $398,000 after buying an additional 9,224 shares during the period. State of Wyoming grew its stake in Medifast by 184.1% during the first quarter. State of Wyoming now owns 32,137 shares of the specialty retailer’s stock worth $433,000 after buying an additional 20,825 shares during the period. Finally, Russell Investments Group Ltd. grew its stake in Medifast by 114.1% during the first quarter. Russell Investments Group Ltd. now owns 19,514 shares of the specialty retailer’s stock worth $267,000 after buying an additional 10,401 shares during the period. Institutional investors and hedge funds own 95.51% of the company’s stock.

About Medifast

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.